Scopus BioPharma is a biopharmaceutical company. Co.'s lead development program is a targeted immuno-oncology gene therapy for the treatment of various cancers. Co. has partnered with the City of Hope for CpG-STAT3siRNA, which is a STAT3 inhibitor gene therapy. Pre-clinical testing at City of Hope was designed to determine whether CO-sTiRNA would reduce growth and metastasis of various pre-clinical tumor models, including melanoma, and colon and bladder cancers, as well as leukemia and lymphoma. Co.'s second lead development program is MRI-1867, a peripherally-restricted, dual-action cannabinoid-1 receptor inverse agonist and inhibitor of inducible nitric oxide synthase. The SCPS stock yearly return is shown above.
The yearly return on the SCPS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SCPS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|